Mimix™ Prostate Cancer Panel Negative Control, cfDNA Reference Standard

The Prostate Cancer Panel cfDNA Reference Standard (Negative Control) is a well characterized, cell line-derived control material manufactured under ISO:13485 that is negative for 17 variants (except CNV in AR Gene) across 9 genes clinically relevant to prostate cancer.

Clearance sale: Discounted pricing on selected cfDNA inventory. Limited availability.*

*This pricing promotion is only valid on selected products and while stocks last. Not valid in Italy and China. The promotion cannot be combined with any other promotions, discounts, or offers. Conditions of the promotions may change, and Revvity may void, change, cancel, suspend, or amend this promotion without notice.

For a limited time only, buy any 2 of the same Mimix reference standard products and get the 3rd FREE!*

*This promotion is only valid in China from 1st July 2025 to 30th September 2025 and on products of the same part number. The promotion cannot be combined with any other promotions, discounts, or offers. Conditions of the promotion may change, and Revvity may void, change, cancel, suspend, or amend this promotion without notice.

The Prostate Cancer Panel cfDNA Reference Standard Negative Control is a well characterized, cell line-derived control material manufactured under ISO:13485 that includes 9 clinically relevant genes that are confirmed negative for 17 variants, except CNV in AR gene. This exciting new Multigene Multiplex product allows labs to perform fast, more reliable, and cost-effective validation of prostate cancer sequencing assays - saving the user time and money to achieve their quality assurance goals faster and allowing the user to assess the performance of cfDNA assays.

Technical data

Format: cfDNA

Genes covered: TP53, AR, PIK3CA, RB1, CDKN2A, STK11, PTEN, BRCA1, BRCA2

Allelic frequencies: 0% (AR gene CNV = 1)

Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0

Product information

Fragment size: 160 bp

Unit size: 350 ng per vial

Concentration: 20 ng/µl

Verified mutations:

Gene	DNA sequence change	Amino acid change	Expected allelic frequency (%)
TP53	c.992A>G	p.Q331R	0.00
TP53	c.742C>T	p.R248W	0.00
TP53	c.668C>T	p.P223L	000
TP53	c.820G>T	p.V274F	0.00
TP53	c.414_del	p.K139Rfs*31	0.00
AR	c.2623C>T	p.H875Y	0.00
AR	c.2623A>G	p.T878A	0.00
PIK3CA	c.1637A>G	p.Q546R	0.00
PIK3CA	c.1624G>A	p.E542K	0.00
RB1	c.2143A>T	p.K715*	0.00
CDKN2A	c.250G>T	p.D84Y	0.00
STK11	c.532_536del	p.KP178Gfs*86	0.00
PTEN	c.17_18del	p.K6Rfs*4	0.00
BRCA1	c.5329dup c.5263_5264insC	p.Q1777Pfs74 p.Q1756Pfs74	0.00
BRCA2	c.9924C>G	p.Y3308*	0.00
AR**	Gain	Gain	1 Copies
PTEN	Loss	Loss	0 Copies

**Since the negative control has 1 copy of AR gene, the final copy number may vary if this panel is used to dilute the positive control panel (HD836).

General information

Storage: 4°C

Expiration: See all product shelf life information

Quality control

Fragmentation size: D1000 DNA ScreenTape assay

Allelic frequency: Droplet Digital™ PCR

Quantification: Qubit® dsDNA BR assay (Invitrogen)

Intended use: For assay developers and molecular diagnostic labs for routine performance monitoring of molecular biology assays. Research use only. Not for diagnostic procedures.